TISSUE REGENIX GROUP PLC — Director's Dealing 2015

Oct 23, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2169D

Tissue Regenix Group PLC

23 October 2015

Tissue Regenix Group Plc

Non- Executive Director Share Purchase

York, 23 October 2015 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Company"), the regenerative medical devices company, today announces that on 21 October 2015 Alan Miller, Non-Executive Director of Tissue Regenix, acquired 400,000 ordinary shares of 0.5 pence at a price of 16.75p per share. 

Following this transaction Alan Miller holds 21,886,988 ordinary shares which represents a total of 2.88% of the Company's issued share capital. 

For Further Information

Tissue Regenix Group Plc:                                                           +44 19 0456 7609

Caitlin Pearson

Corporate Communications Officer

c.pearson@tissueregenix.com

Jefferies International Ltd:                                                         +44 20 7029 8000

Simon Hardy

Harry Nicholas

Tulchan Communications:                                                           +44 207 353 4200

James Macey White

Matt Low

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSDMMZGVFDGKZG